Product review: Avelumab, an anti-PD-L1 antibody

Collins, Julie M.; Gulley, James L.

doi:10.1080/21645515.2018.1551671

Cited by 91Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesPolyomavirus and related diseases

Product review: Avelumab, an anti-PD-L1 antibody

Open access

Collins, Julie M., Gulley, James L.·2019·Human Vaccines & Immunotherapeutics

DOI 10.1080/21645515.2018.1551671PMC PMC6605872

Open this paper in CoChat — free account

Abstract

Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor microenvironment and reducing tumor growth. Most early clinical trials of avelumab as monotherapy and in combination regimens were part of the international JAVELIN clinical trial program, which included more than 7000 patients in more than 30 trials with at least 15 tumor types. Avelumab has been approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum-based regimen. Its acceptable safety profile and ability to induce durable responses in otherwise deadly tumors provide the rationale for its use in other tumor types and in combination with other therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/21645515.2018.1551671

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Avelumab was approved by the FDA for patients with metastatic Merkel cell carcinoma, regardless of previous chemotherapy, in March 2017.
“In March 2017, avelumab was finally designated as a breakthrough therapy and was approved by the FDA for patients with metastatic MCC, regardless of previous chemotherapy [63].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [63]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1× · see citing works
“The overall ORR of this study compares favorably to ORRs in previous studies of ICIs in which patients were less heavily pre-treated and ocular melanoma was excluded; ORRs were approximately 33% with pembrolizumab, 12% with ipilimumab, and 40% with the combination of ipilimumab plus nivolumab in otherwise similar pati…”
Result
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · see citing works
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works
Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208 · see citing works
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · see citing works
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · see citing works
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · see citing works
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works
Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Sharma, P., Retz, M. M., Siefker-Radtke, A. O., Baron, A. D., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D. A., Grimm, M., Sergio Bracarda, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,729 · see citing works
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,287 · see citing works
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,282 · see citing works
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,277 · see citing works
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,257 · see citing works
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · see citing works
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 944 · see citing works
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 879 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Valsecchi, M. E. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 874 · see citing works
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869 · see citing works
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N. B., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 848 · see citing works
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Tsao, M., Kerr, K. M., Kockx, M. M., Beasley, M. B., Borczuk, A., Botling, J., Bubendorf, L., Chirieac, L. R., Chen, G., Chou, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 805 · see citing works
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787 · see citing works
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt, B., Théodore, C., Demkov, T., Komyakov, B. K., Sengeløv, L., Daugaard, G., Caty, A., Carles, J., Jagiełło-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766 · see citing works
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Dirix, L. Y., Takács, I., Jérusalem, G., Nikolinakos, P. G., Arkenau, H., Forero, A., Boccia, R. V., Lippman, M. E., Somer, R. A., Šmakal, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 748 · see citing works
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747 · see citing works
Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution
Allen, P. J., Bowne, W. B., Jaques, D. P., Brennan, M. F., BUSAM, K. J., & Coit, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.329 · Cited by 735 · see citing works
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 717 · see citing works
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Sharma, P., Callahan, M. K., Bono, P., Kim, J. W., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 676 · see citing works
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S. J., Keegan, P., & Pazdur, R. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664 · see citing works
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 652 · see citing works
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Scheuer, W., Friess, T., BURTSCHER, H. J., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 624 · see citing works
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
Bedikian, A. Y., Millward, M. J., Pehamberger, H., Conry, R. M., Gore, M. E., Trefzer, U., Pavlick, A. C., DeConti, R. C., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600 · see citing works
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590 · see citing works
Self-citation
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585 · see citing works
Self-citation
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
Avril, M.-F., Aamdal, S., Grob, J., Hauschild, A., Mohr, P., Bonerandi, J. J., Weichenthal, M., Neuber, K., Bieber, T. R. M., Gilde, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.165 · Cited by 486 · see citing works
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Alley, E. W., Lopez, J. S., Santoro, A., Morosky, A., Saraf, S., Piperdi, B., & van Brummelen, E. M. J. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30169-9 · Cited by 486 · see citing works
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473 · see citing works
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Boyerinas, B., Jochéms, C., Fantini, M. C., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 468 · see citing works
Self-citation
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Schalper, K. A., Velcheti, V., Carvajal, D. E., Wimberly, H., Brown, J. R., Pusztai, L., & Rimm, D. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2702 · Cited by 449 · see citing works
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Hutson, T. E., Lesovoy, V., Al-Shukri, S. K., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404 · see citing works
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Wimberly, H., Brown, J. R., Schalper, K. A., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 395 · see citing works
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Goh, G., Walradt, T. J., Markarov, V., Blom, A., Riaz, N., Doumani, R., Stafstrom, K., Moshiri, A. S., Yelistratova, L., Levinsohn, J. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6494 · Cited by 387 · see citing works
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
D’Angelo, S. P., Russell, J. S., Lebbé, C., Chmielowski, B., Gambichler, T., Grob, J., Kiecker, F., Rabinowits, G., Terheyden, P. A. M., Zwiener, I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0077 · Cited by 377 · see citing works
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370 · see citing works
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Tótpál, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 365 · see citing works
Chemotherapy in Neuroendocrine/Merkel Cell Carcinoma of the Skin: Case Series and Review of 204 Cases
Tai, P. T. H., Yu, E. W., Winquist, E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2493 · Cited by 353 · see citing works
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
Mansfield, A. S., Aubry, M., Moser, J. C., Harrington, S. M., Dronca, R. S., Park, S. S., & Dong, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw289 · Cited by 338 · see citing works
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Cimino‐Mathews, A., Thompson, E. D., Taube, J. M., Ye, X., Yao, L., Meeker, A. K., Xu, H., Sharma, R. B., Lecksell, K., Cornish, T. C., et al. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336 · see citing works
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
Webb, J. R., Milne, K., Kroeger, D. R., & Nelson, B. H. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.008 · Cited by 335 · see citing works
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0310-x · Cited by 334 · see citing works
Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature
Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31043 · Cited by 328 · see citing works
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325 · see citing works
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Bichakjian, C. K., Olencki, T. E., Aasi, S. Z., Alam, M., Andersen, J., Blitzblau, R. C., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0055 · Cited by 317 · see citing works
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Tartour, É., Péré, H., Maillère, B., Terme, M., Merillon, N., Taı̈eb, J., Sandoval, F., Quintin‐Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316 · see citing works
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Heery, C. R., Coyne, G. O., Madan, R. A., Cordes, L. M., Rajan, A., Rauckhorst, M., Lamping, E., Oyelakin, I., Marté, J. L., Lepone, L. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30239-5 · Cited by 308 · see citing works
Self-citation
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
Gulley, J. L., Rajan, A., Spigel, D. R., Iannotti, N. O., Chandler, J. C., Wong, D. J. L., Leach, J. W., Edenfield, W. J., Wang, D., Grote, H. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30240-1 · Cited by 286 · see citing works
Self-citation
T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival
Boorjian, S. A., Sheinin, Y. M., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0731 · Cited by 270 · see citing works
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., Downs, T. M., Efstathiou, J. A., Flaig, T. W., Friedlander, T. W., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0156 · Cited by 268 · see citing works
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Thomas, A., Routh, E. D., Pullikuth, A., Jin, G., Su, J., Chou, J. W., Hoadley, K. A., Print, C. G., Knowlton, N. S., Black, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490854 · Cited by 262 · see citing works
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
Iyer, J. G., Blom, A., Doumani, R., Lewis, C. W., Tarabadkar, E. S., Anderson, A., Ma, C., Bestick, A., Parvathaneni, U., Bhatia, S., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.815 · Cited by 260 · see citing works
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30107-4 · Cited by 260 · see citing works
Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
Sweeney, C. J., Roth, B. J., Kabbinavar, F. F., Vaughn, D. J., Arning, M., Curiel, R. E., Obasaju, C. K., Wang, Y., Nicol, S. J., & Kaufman, D. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6699 · Cited by 244 · see citing works
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
Mansfield, A. S., Roden, A. C., Peikert, T., Sheinin, Y. M., Harrington, S. M., Krco, C. J., Dong, H., & Kwon, E. D. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000177 · Cited by 237 · see citing works
Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States
Fitzgerald, T. L., Dennis, S. O., Kachare, S. D., et al. (2015) · The American Surgeon · doi:10.1177/000313481508100819 · Cited by 221 · see citing works
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
Cedrés, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A. B., Navarro, A., Martínez‐Martí, A., Martínez, P., & Felip, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121071 · Cited by 218 · see citing works
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L. O., Stein, M. N., Poplin, E. A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 209 · see citing works
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
Udall, M., Rizzo, M., Kenny, J., Doherty, J. P., Dahm, S., Robbins, P. B., & Faulkner, E. C. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0689-9 · Cited by 209 · see citing works
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · see citing works
Systemic Therapy for Ovarian Cancer: Current Status and New Treatments
Ozols, R. F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.011 · Cited by 189 · see citing works
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Hazarika, M., Chuk, M. K., Theoret, M. R., Mushti, S. L., He, K., Weis, S. L., Putman, A. H., Helms, W. S., Cao, X., Li, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0712 · Cited by 184 · see citing works
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw141 · Cited by 178 · see citing works
Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
Rios‐Doria, J., Durham, N. M., Wetzel, L. K., Rothstein, R. P., Chesebrough, J. W., Holoweckyj, N., Zhao, W., Leow, C. C., & Hollingsworth, R. E. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.004 · Cited by 174 · see citing works
Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?
Poulsen, M. G., Rischin, D., Porter, I., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.04.042 · Cited by 168 · see citing works
Erratum: Targeting neoantigens to augment antitumour immunity
Yarchoan, M. M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.74 · Cited by 163 · see citing works
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
Stebbing, J., Powles, T. B., McPherson, K., Shamash, J., Wells, P., Sheaff, M. T., Slater, S., Rudd, R., Fennell, D. A., & Steele, J. P. C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.04.001 · Cited by 153 · see citing works
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Ceresoli, G. L., Zucali, P. A., Vincenzo, F. D., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.004 · Cited by 149 · see citing works
Merkel Cell Carcinoma: 30-Year Experience from a Single Institution
Santamaria‐Barria, J. A., Boland, G. M., Yeap, B. Y., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2779-3 · Cited by 144 · see citing works
Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.
Disis, M. L., Patel, M. R., Pant, S., Hamilton, E. P., Lockhart, A. C., Kelly, K. L., Beck, J. T., Gordon, M. S., Weiss, G. J., Taylor, M. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5533 · Cited by 143 · see citing works
Self-citation
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Mansfield, A. S., Murphy, S. J., Peikert, T., Yi, E. S., Vasmatzis, G., Wigle, D. A., & Aubry, M. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2246 · Cited by 134 · see citing works
Seamless Oncology-Drug Development
Prowell, T. M., Theoret, M. R., & Pazdur, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1603747 · Cited by 126 · see citing works
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
Cowey, C. L., Mahnke, L. A., Espirito, J. L., Helwig, C., Oksen, D., & Bharmal, M. F. (2017) · Future Oncology · doi:10.2217/fon-2017-0187 · Cited by 118 · see citing works
Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses
Schmid, P., Cruz, C., Braiteh, F. S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2986 · Cited by 115 · see citing works
Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor
Vandeveer, A. J., Fallon, J. K., Tighe, R., Sabzevari, H., Schlom, J., & Greiner, J. W. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0176 · Cited by 102 · see citing works
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
Zucali, P. A., Ceresoli, G. L., Garassino, I. M. G., et al. (2008) · Cancer · doi:10.1002/cncr.23337 · Cited by 101 · see citing works
T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Lyngaa, R., Pedersen, N. W., Schrama, D., Thrue, C. A., Ibrani, D., Met, Ö., Straten, P. T., Nghiem, P., Becker, J. C., & Hadrup, S. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2697 · Cited by 100 · see citing works
Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin
Kandalaft, L. E., Motz, G. T., Busch, J. I., & Coukos, G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_95 · Cited by 96 · see citing works
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Donahue, R. N., Lepone, L. M., Grenga, I., Jochéms, C., Fantini, M. C., Madan, R. A., Heery, C. R., Gulley, J. L., & Schlom, J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0220-y · Cited by 92 · see citing works
Self-citation
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Kelly, K. L., Infante, J. R., Taylor, M. H., Patel, M. R., Wong, D. J. L., Iannotti, N. O., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I., et al. (2018) · Cancer · doi:10.1002/cncr.31293 · Cited by 92 · see citing works
Self-citation
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H. P., Patel, M. R., Gravenor, D. S., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L. S., Lee, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0459-y · Cited by 82 · see citing works
Self-citation
Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Chung, H. C., Arkenau, H., Lee, J., Rha, S. Y., Oh, D. Y., Wyrwicz, L. S., Kang, Y., Lee, K., Infante, J. R., Lee, S. S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0508-1 · Cited by 82 · see citing works
Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design
Pujade-Lauraine, É., Fujiwara, K., Dychter, S. S., Devgan, G., & Monk, B. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0070 · Cited by 75 · see citing works
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.
Chung, H. C., Arkenau, H., Wyrwicz, L. S., Oh, D., Lee, K., Infante, J. R., Lee, S. S., Lee, J., Keilholz, U., Mita, A. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4009 · Cited by 62 · see citing works
Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
Shaw, A. T., Lee, S., Ramalingam, S. S., Bauer, T. M., Boyer, M. J., Carcereny, E., Felip, E., Han, J., Hida, T., Hughes, B. G. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9008 · Cited by 60 · see citing works
A fully human IgG1 anti‐PD‐L1 MAb in an in vitro assay enhances antigen‐specific T‐cell responses
Grenga, I., Donahue, R. N., Lepone, L. M., Richards, J., & Schlom, J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.27 · Cited by 56 · see citing works
Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
Jardim, D. L. F., Gagliato, D. D. M., Giles, F. J., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1970 · Cited by 54 · see citing works
Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma
Nehls, O., Klump, B., Holzmann, K., Lammering, G., Borchard, F., Gruenagel, H. H., Gaco, V., Gregor, M., & Porschen, R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990615)85:12 · Cited by 38 · see citing works
Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
Apolo, A. B., Ellerton, J. A., Infante, J. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4528 · Cited by 35 · see citing works
Nonprogression with Avelumab Treatment Associated with Gains in Quality of Life in Metastatic Merkel Cell Carcinoma
Kaufman, H. L., Hünger, M., Hennessy, M. G., Schlichting, M., & Bharmal, M. F. (2017) · Future Oncology · doi:10.2217/fon-2017-0470 · Cited by 31 · see citing works
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
Stein, A., Binder, M., Al‐Batran, S., Hinke, A., Waberer, L., Goekkurt, E., Meyer, T., Statovci, D., Depenbusch, R., Riera‐Knorrenschild, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3561 · Cited by 24 · see citing works
Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.
Keilholz, U., Mehnert, J. M., Bauer, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.191 · Cited by 21 · see citing works
Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).
Tao, Y., Auperin, A., Sun, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6076 · Cited by 19 · see citing works
Necitumumab for non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1055243 · Cited by 17 · see citing works
Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients
Apolo, A. B., Ellerton, J. A., Infante, J. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx371.010 · Cited by 17 · see citing works
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma
Okuno, S. H., Delaune, R., Sloan, J. A., et al. (2008) · Cancer · doi:10.1002/cncr.23313 · Cited by 16 · see citing works
A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
Powles, T. B., Grivas, P. D., Aragon‐Ching, J. B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw373.69 · Cited by 14 · see citing works
Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.
Gulley, J. L., Spigel, D. R., Kelly, K. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9086 · Cited by 14 · see citing works
Self-citation
Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Shitara, K., Yamada, Y., Yoh, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3023 · Cited by 13 · see citing works
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.
Kelly, K. L., Heery, C. R., Patel, M. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3055 · Cited by 12 · see citing works
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.
Bhatia, S., Brohl, A. S., Brownell, I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps9605 · Cited by 12 · see citing works
Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies
Zhang, Y., He, Y., Li, L., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0727-7 · Cited by 11 · see citing works
Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer
Mayer, E., Wander, S., Regan, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-ot3-05-11 · Cited by 10 · see citing works
Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.
Rajan, A., Gulley, J. L., Spigel, D. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9090 · Cited by 7 · see citing works
Self-citation
Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.
Hassan, R., Thomas, A., Nemunaitis, J. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.166 · Cited by 6 · see citing works
Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial
Chung, H. C., Arkenau, H., Lee, J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct111 · Cited by 6 · see citing works
Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.
D’Angelo, S. P., Hünger, M., Schlichting, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.193 · Cited by 5 · see citing works
Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).
Walker, J. W. T., Kasturi, V., Lebbé, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9537 · Cited by 5 · see citing works
Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.
Vida, A. R., Mellado, B., del Muro, X. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps4591 · Cited by 5 · see citing works
Avelumab as neoadjuvant therapy in subjects with muscle-invasive urothelial carcinoma (AURA trial).
Chanzá, N. M., Roumeguere, T. A., Sideris, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.tps535 · Cited by 4 · see citing works
Safety of axitinib plus avelumab in patients with recurrent glioblastoma.
Salama, L. B., Duerinck, J., Four, S. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e14082 · Cited by 4 · see citing works
Radiotherapy with concurrent Avelumab and Cetuximab as primary treatment in patients with locally advanced squamous cell carcinoma of the head and neck: A phase-IB feasibility trial in patients unfit for cisplatin (NCT02938273).
Elbers, J. B. W., Zuur, C. L., Tesselaar, M. E. T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e18019 · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216 · see citing works

Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma
Koljonen, V., Kukko, H., Pukkala, ., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605306 · Cited by 138 · see citing works
Detection of Polyomavirus in Merkel cell carcinoma by immunohistochemistry: report of three cases.
Vaira, F., Nazzaro, G., Pesapane, F., et al. (2015) · PubMed · Cited by 4 · see citing works
Detection of Merkel cell polyomavirus in cutaneous squamous cell carcinoma before occurrence of Merkel cell carcinoma
Kaibuchi-Noda, K., Yokota, K., Matsumoto, T., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.026 · Cited by 10 · see citing works
Merkel Cell Polyomavirus Strains in Patients with Merkel Cell Carcinoma
Touzé, A., Gaitan, J., Maruani, A., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1506.081463 · Cited by 77 · see citing works
Seeking Standards for the Detection of Merkel Cell Polyomavirus and its Clinical Significance
Eid, M., Nguyen, J., & Brownell, I. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.12.024 · Cited by 19 · see citing works

Authors: Collins, J. M., & Gulley, J. L.
Affiliations: National Institutes of Health (US)
Corresponding author: Gulley, James L.
ORCID: Collins, Julie M.
Gulley, James L.
Venue: Human Vaccines & Immunotherapeutics
Publisher: Informa UK Limited
Published: 2018-12-20
Volume: 15
Issue: 4
Pages: 891-908
ISSN: 2164-5515 (ISSN-L)
2164-554X
DOI: 10.1080/21645515.2018.1551671
PMC: PMC6605872
OpenAlex: W2903323937
Cited by: 91
References: 137
Citations by year: 2026: 8 · 2025: 19 · 2024: 14 · 2023: 13 · 2022: 15 · 2021: 14 · 2020: 5 · 2019: 2 · 2013: 1
FWCI: 1.97
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Keywords: avelumab, PD-L1 inhibitors, immune checkpoint inhibitors, PD-1/PD-L1 interaction, immunosuppressive tumor microenvironment, metastatic Merkel cell carcinoma, metastatic urothelial carcinoma, combination immunotherapy
MeSH terms: Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Carcinoma, Merkel Cell, Urothelium, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Product review: Avelumab, an anti-PD-L1 antibody

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks